FILSPARI (sparsentan) was approved in February 2023 as a once-daily treatment to lower proteinuria in adults with primary IgA nephropathy.
FILSPARI is a prescription medicine to lower protein in the urine (proteinuria) in adults with primary IgA nephropathy who are at risk of their disease quickly getting worse. It is not known if FILSPARI is safe and effective in children.
FILSPARI has been approved based on a reduction of proteinuria. Continued approval may require results from an ongoing study to determine whether FILSPARI slows decline in kidney function.
For appropriate adult patients, FILSPARI is only available through a Risk Evaluation and Mitigation Strategy (REMS) Program because of the serious risk of liver problems and serious birth defects.
Download this brochure [https://www.filspari.com/igan/filspari-brochure-igan.pdf] to learn more about FILSPARI and talk to your doctor to see if its right for you.
